BFS
RGNX icon

Bradley Foster & Sargent’s Regenxbio RGNX Stock Holding History

Bradley Foster & Sargent’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,699
Closed -$224K – 548
2026
Q1 		$224K Sell
26,699
-23,650
-47% -$248K ﹤0.01% 506
2025
Q4 		$725K Buy
50,349
+147
+0.3% +$1.83K 0.01% 332
2025
Q3 		$484K Sell
50,202
-4,685
-9% -$41.4K 0.01% 393
2025
Q2 		$451K Buy
+54,887
New +$459K 0.01% 402

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bradley Foster & Sargent's RGNX Position: Q2 2026 in Review

Bradley Foster & Sargent sold out of Regenxbio (RGNX) in Q2 2026, closing a stake of 26,699 shares — an estimated $224K sold.

Bradley Foster & Sargent first reported a position in RGNX in Q2 2025 and held it in 4 quarters. The position peaked at $725K in Q4 2025. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Bradley Foster & Sargent reported no remaining Regenxbio position as of Q2 2026 after selling out during the quarter.
  • Bradley Foster & Sargent sold 26,699 Regenxbio shares in Q2 2026, an estimated $224K.
  • Bradley Foster & Sargent first reported a position in Regenxbio in Q2 2025 and held it in 4 quarters.
  • Bradley Foster & Sargent's Regenxbio position peaked at $725K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Bradley Foster & Sargent's 13F filing for Q2 2026, filed 14 Aug 2026.